DUBLIN–(BUSINESS WIRE)–The “Pneumococcal Infections – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This Pneumococcal infections – Pipeline Insight, 2021 report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Pneumococcal infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The companies and academics are working to assess challenges and seek opportunities that could influence Pneumococcal infections R&D. The therapies under development are focused on novel approaches to treat/improve Pneumococcal infections.
Pneumococcal infections Emerging Drugs Chapters
This segment of the Pneumococcal infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pneumococcal infections Emerging Drugs
20-Valent Pneumococcal Conjugate Vaccine: Pfizer
On September 20, 2018, Pfizer announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for…